发明名称 |
Antibodies for the treatment of HIV |
摘要 |
The present invention relates to novel isolated antibodies, or the derivatives or antigen binding fragments of same, capable of binding to CXCR4 but also of inducing conformational changes of the CXCR4 homodimers and able to inhibit HIV-1 primary isolate replication in PBMC. More particularly, the present invention relates to the 515H7 and 301aE5 monoclonal antibodies, specific to the CXCR4 protein, as well as their use for the treatment of HIV infection. Pharmaceutical compositions comprising such antibodies and a process for the selection of such antibodies are also covered. |
申请公布号 |
US9090686(B2) |
申请公布日期 |
2015.07.28 |
申请号 |
US201012913300 |
申请日期 |
2010.10.27 |
申请人 |
Pierre Fabre Medicament |
发明人 |
Klinguer-Hamour Christine |
分类号 |
A61K39/395;C07K16/28;C07K16/24;A61K31/439;A61K45/00;A61K39/00 |
主分类号 |
A61K39/395 |
代理机构 |
Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. |
代理人 |
Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. |
主权项 |
1. A recombinant anti-CXCR4 antibody or a CXCR4-binding fragment thereof, wherein said antibody or binding fragment comprises a light chain comprising CDR-L1, CDR-L2 and CDR-L3 comprising respectively the amino acid sequence of SEQ ID Nos. 1, 2 and 30; and a heavy chain comprising CDR-H1, CDR -H2 and CDR-H3 comprising respectively the amino acid sequence of SEQ ID Nos. 31, 32 and 33. |
地址 |
Boulogne-Billancourt FR |